febuxostat has been researched along with Acute Liver Injury, Drug-Induced in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hiramatsu, SI; Ikemura, K; Iwamoto, T; Katayama, N; Nakatani, Y; Okuda, M; Shinogi, Y; Tawara, I | 1 |
| Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L | 1 |
| Kataoka, H; Rock, KL; Yang, K | 1 |
| Bohm, M; Chalasani, N; Vuppalanchi, R | 1 |
2 review(s) available for febuxostat and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2021 |
4 other study(ies) available for febuxostat and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Synergism; Febuxostat; Female; Gout Suppressants; Hematopoiesis; Humans; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Male; Methotrexate; Middle Aged; Neoplasm Proteins | 2019 |
The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Death; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Gastroesophageal Reflux; Gout Suppressants; Liver; Lung; Lung Injury; Male; Mice, Inbred C57BL; Necrosis; Neutrophil Infiltration; Peritoneum; Peritonitis; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat-induced acute liver injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Liver; Male | 2016 |